What do systematic reviews say?

Bowman-Birk inhibitor vs placebo or no treatment

• Interventions for treating oral leukoplakia to prevent oral cancer 2016 · Cochrane All outcomes
  SoF 6, Histological changes: 'Not measured'. Effects text: data on histological changes from Armstrong 2013 were not available for analysis, but study authors reported no statistically significant differences in…
  1 study
  GRADE not reported

Bowman-Birk inhibitor vs placebo or no treatment

Bowman-Birk inhibitor showed no clear difference in clinical resolution (oral lesion not completely resolved) compared with placebo or no treatment (low certainty).

• Interventions for treating oral leukoplakia to prevent oral cancer 2016 · Cochrane All outcomes

  6 months
  RR 1.00 [0.91, 1.09]
  1 study · 21 participants
  Low

Bowman-Birk inhibitor vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions for treating oral leukoplakia to prevent oral cancer 2016 · Cochrane All outcomes
  SoF 6 (Bowman-Birk inhibitor vs placebo), Cancer development: 'Not measured'. Effects text: 'Cancer development was not among the outcomes of the study testing the Bowman-Birk inhibitor (Armstrong 2013).'
  0 studies
  No studies found

Bowman-Birk inhibitor vs placebo or no treatment

• Interventions for treating oral leukoplakia to prevent oral cancer 2016 · Cochrane All outcomes

  up to 6 months
  SoF 6, Safety of the intervention up to 6 months: 'Trial authors reported that there were no significant adverse effects. 33 participants in the intervention group reported 75 adverse effects. 25 participants in the…
  1 study
  GRADE not reported